Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of the epidermal growth factor receptor (EGFR), and CD3 on T-cells, thereby directing immune...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Ellwanger, Kristina, Reusch, Uwe, Fucek, Ivica, Knackmuss, Stefan, Weichel, Michael, Gantke, Thorsten, Molkenthin, Vera, Zhukovsky, Eugene A., Tesar, Michael, Treder, Martin
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2017
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5442391/
https://ncbi.nlm.nih.gov/pubmed/28596941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00100
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares